Pharmacokinetics of non-steroidal anti-inflammatory drugs and ENT diseases;Pharmacologie des anti-inflammatoires non-stéroïdiens et pathologies ORL

Presse Medicale

Volumn 30, Issue 39-40, 2001, Pages 70-79

  Devillier, Philippe ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BRADYKININ; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; HISTAMINE; LYSINE ACETYLSALICYLATE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PROSTAGLANDIN; PROSTANOID; ROFECOXIB; SEROTONIN;

ALLERGIC RHINITIS; ANALGESIA; ANTIINFLAMMATORY ACTIVITY; ANTIPYRETIC ACTIVITY; ASTHMA; BLEEDING TIME; DRUG EFFICACY; DRUG MECHANISM; EAR NOSE THROAT DISEASE; GASTROINTESTINAL SYMPTOM; HUMAN; NOSE POLYP; OSTEOARTHRITIS; POLYPECTOMY; REVIEW; RHEUMATOID ARTHRITIS; TERATOGENESIS; THERMOREGULATION; THROMBOCYTE AGGREGATION INHIBITION;

EID: 0035936375     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (91)

1. Anti-inflammatoires non stéroïdiens
2. Prostaglandines: Nomenclature et biosynthèse
3. International union of pharmacology. Classification of prostanoid receptors: Properties, distribution and structure of the receptors and their subtypes
4. 60 to Leu mutation
5. Vascular biology of the isoprostanes
6. La complexité des aspects physiopharmacologiques de la douleur
7. The role of IP prostanoid receptors in inflammatory pain
8. The intraspinal release of prostaglandin E2 in a model of acute arthritis is accompanied by an up-regulation of cyclo-oxygenase-2 in the spinal cord
9. The mechanisms of action of NSAIDs in analgesia
10. Involvement of primary afferent C-fibres in touch-evoked pain (allodynia) induced by prostaglandin E2
11. Analysis of the effects of cyclooxygenase (COX)-1 and COX-2 in spinal nociceptive transmission using indomethacin, a non-selective COX inhibitor, and NS-398, a COX-2 selective inhibitor
12. Cyclo-oxygénases: Concept et modèles d'études
13. Isoenzymes de la cyclo-oxygénase et anti-inflammatoires non stéroïdiens
14. Cyclo-oxygenases: Pharmacology, physiology, biochemistry and relevance to NSAID therapy
15. Selectivity of non steroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenases
16. Non steroidal antiinflammatory drugs - Differences and similarities
17. The mechanisms of action of NSAIDs in analgesia
18. Spinal cord effects of antipyretic analgesics
19. Antiinflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: A randomized controlled trial
20. Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model
21. Analgesic efficacy of the cyclooxygenase-2-specific inhibitor rofecoxib in post-dental surgery pain: A randomized, controlled trial
22. Comparison of rofecoxib and celecoxib, two cyclooxygenase-2 inhibitors, in postoperative dental pain: A randomized, placebo- and active-comparator-controlled clinical trial
23. Cyclooxygenase-2 inhibition by rofecoxib reverses naturally occurring fever in humans
24. Analgésiques non morphiniques
25. Acetaminophen inhibits spinal prostaglandin E2 release after peripheral noxious stimulation
26. Diclofenac or acetaminophen for analgesia in paediatric tonsillectomy outpatients
27. Essai comparatif de l'acétylsalycilate de lysine et du paracétamol sur les douleurs de pratique médicale courante
28. Gastrointestinal health care resource use and costs associated with nonsteroidal antiinflammatory drugs versus acetaminophen: Retrospective cohort study of an elderly population
29. Release of chemical mediators and inflammatory cell influx during early allergic reaction in the nose: Effect of furosemide
30. Intranasal salmeterol inhibits allergen-induced vascular permeability but not mast cell activation or cellular infiltration
31. Pathophysiology of allergic rhinitis
32. Arachidonic acid metabolites during nasal challenge
33. The effect of BAY u 3405, a thromboxane receptor antagonist, on prostaglandin D2-induced nasal blockage
34. Nasal response to a single antigen challenge in patients with allergic rhinitis. Inflammatory cell recruitment persists up to 48 hours
35. Effects of aspirin on nasal responses in atopic subjects
36. Effect of flurbiprofen, a cyclooxygenase inhibiting drug, on induced allergic rhinitis
37. Treatment of ragweed hay fever with flurbiprofen, a cyclooxygenase-inhibiting drug
38. Indirect evidence of nasal inflammation assessed by titration of inflammatory mediators and enumeration of cells in nasal secretions of patients with chronic rhinitis
39. Relationship between nasal hyperreactivity, mediators and eosinophils in patients with perennial allergic rhinitis and controls
40. Are prostaglandins major mediators in perennial allergic rhinitis?
41. Cyclooxygenase and lipoxygenase metabolite generation in nasal polyps
42. Arachidonic acid metabolites in human nasal polyps
43. Arachidonic acid metabolism in nasal tissue and peripheral blood cells in aspirin intolerant asthmatics
44. Cyclooxygenase-2 mRNA is downexpressed in nasal polyps from aspirin-sensitive asthmatics
45. Effects of lysine-acetylsalicylate (LAS) treatment in nasal polyposis: Two controlled long term prospective follow up studies
46. Chronic sinusitis: Characterization of cellular influx and inflammatory mediators in sinus lavage fluid
47. Assessment of inflammation in noninfectious chronic maxillary sinusitis
48. Expression of cyclo-oxygenase 1 and 2 proteins in upper respiratory mucosa
49. Prostaglandin content in human middle ear effusions
50. Naproxen in otitis media with effusion
51. Arachidonic acid metabolites in experimental otitis media and effects of anti-inflammatory drugs
52. Arachidonic acid metabolites in middle ear effusions of children
53. Early biochemical events in pneumococcal otitis media: Arachidonic acid metabolites in middle ear fluid
54. Eicosanoid synthesis and inactivation in healthy and infected chinchilla middle ears
55. Expression of acute otitis media after receptor blockade of platelet activating factor, thromboxane, and leukotrienes in the chinchilla
56. Treatment of experimental acute otitis media with ibuprofen and ampicillin
57. Effect of naproxen, a prostaglandin inhibitor, on acute otitis media and persistence of middle ear effusion in children
58. A randomized, double-blind, multicentre controlled trial of ibuprofen versus acetaminophen and placebo for symptoms of acute otitis media in children
59. The role of inflammatory mediators and anti-inflammatory drugs in otitis media
60. A controlled trial comparing three treatments for chronic otitis media with effusion
61. Gastrointestinal effects of non steroidal anti-inflammatory therapy
62. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs
63. Risk for serious gastrointestinal complications related to use of non steroidal anti-inflammatory drugs
64. Epidemiology of nonsteroidal antiinflammatory drug-induced gastrointestinal complications
65. Association of upper gastrointestinal toxicity of non steroidal anti-inflammatory drugs with continued exposure: Cohort study
66. Individual nonsteroidal antiinflammatory drugs and other risk factors for upper gastrointestinal bleeding and perforation
67. Risk of upper gastro-intestinal bleeding and perforation associated with individual nonsteroidal anti-inflammatory drugs
68. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: Results of a collaborative meta-analysis
69. Low-dose diclofenac, naproxen, and ibuprofen cohort study
70. Variability in risk of gastrointestinal complications with different nonsteroidal anti-inflammatory drugs
71. Diclofénax et tolérance digestive. Revue de la littérature internationale après 20 ans de prescription
72. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract breeding/perforation: An overview of epidemiologic studies published in the 1990s
73. Safety of meloxicam: A global analysis of clinical trials
74. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthtitis and rheumatoid arthritis: The CLASS study: A randomized controlled trial Celecoxib Long-term Arthritis Safety Study
75. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: A randomized controlled trial
76. Review Article: The gastrointestinal safety profile of rofecoxib, a highly selective inhibitor of cyclooxygenase-2, in humans
77. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid Arthritis
78. Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis
79. Comparison of the effect of rofecoxib (a cydooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: A randomized, double-blind, placebo-controlled trial
80. A randomized trial comparing the effect of rofecoxib; a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis
81. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: Physiologic foundations and clinical implications
82. Analgesics and the kidney: Summary and recommendations to the scientific advisory board of the National Kidney Foundation from an Ad Hoc Committee of the National Kidney Foundation
83. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids
84. Effects of celecoxib and naproxen on renal function in the elderly
85. Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. A randomized, controlled trial
86. Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adult: A randomized, controlled trial
87. A comparison of ibuprofen and indomethacin for closure of patent ductus arteriosus
88. The clinical potential of cyclo-oxygenase 2-specific inhibitors
89. Safety of a specific COX-2 inhibitor in aspirin-induced asthma